| | Two years after the creators of the CRISPR gene-editing technology won a Nobel Prize for chemistry, the very first gene-editing drug appears to be on a path for approval, reports Sy Mukherjee in his recent article for Fast Company. And it could be on the market as early as next year. The drug, nicknamed exa-cel, has already seen promising clinical results in treating two rare blood diseases. It’s part of a wave of more than 60 new gene and cell therapies that are expected by 2030. “That could lead to a transformation in how we think about incurable conditions,” writes Mukherjee, “with gene and cell therapies potentially being used to treat everything from rare diseases to HIV to heart disease.” Read his story here. —Bobbie Gossage | | | | | |
|
|
| | | Video: brand hit or miss | Taco Bell innovating with a giant Cheez-It? Sure. | Taco Bell has long been known for its fun and delicious brand collaborations, and the latest brings back snack nostalgia in the form of Cheez-Its! Check out this week’s ‘Brand Hit or Miss’ to find out why a Cheez-It 16 times the size of a regular cracker just might be the brand collaboration we all needed. | | | | | | | | | |